# S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct05101070/  
OnCo record `nct05101070` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab and Bevacizumab in advanced solid tumours, run by Shionogi, now recruiting.

## Summary

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05101070 by Shionogi, with 282 participants planned, started 2022-05-30 and due to reach its primary completion in 2028-05-31. Interventions recorded: S-531011, Pembrolizumab and Bevacizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05101070
- Phase: 1/2
- Setting: A Phase 1b/2, Multicenter, Open-label Study of S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
- Sponsor: Shionogi
- Enrolled: 282

## Sources

- ClinicalTrials.gov NCT05101070: https://clinicaltrials.gov/study/NCT05101070

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct05101070.json